MA27431A1 - Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques - Google Patents

Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques

Info

Publication number
MA27431A1
MA27431A1 MA28139A MA28139A MA27431A1 MA 27431 A1 MA27431 A1 MA 27431A1 MA 28139 A MA28139 A MA 28139A MA 28139 A MA28139 A MA 28139A MA 27431 A1 MA27431 A1 MA 27431A1
Authority
MA
Morocco
Prior art keywords
therapeutic agents
agents against
inflammatory
ischemic
against acute
Prior art date
Application number
MA28139A
Other languages
English (en)
Inventor
Heike Gielen-Haertwig
Li Volkhart Min-Jian
Ulrich Rosentreter
Karl-Heinz Schlemmer
Swen Allerheiligen
Leila Telan
Lars Baerfacker
Joerg Keldenich
Mary F Fitzgerald
Kevin Nash
Barbara Albrecht
Dirk Meurer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220962A external-priority patent/GB0220962D0/en
Priority claimed from GB0315870A external-priority patent/GB2392910A/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA27431A1 publication Critical patent/MA27431A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des nouveaux dérivés hétérocycliques, des procédés de préparation de ceux-ci et l'utilisation desdits dérivés dans des médicaments, notamment pour le traitement de maladies obstructives respiratoires, du syndrome coronarien aigu, de l'infarctus aigu du myocarde et du développement d'une insuffisance cardiaque.
MA28139A 2002-09-10 2005-03-10 Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques MA27431A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220962A GB0220962D0 (en) 2002-09-10 2002-09-10 Heterocyclic derivatives
GB0226609A GB0226609D0 (en) 2002-09-10 2002-11-14 Heterocyclic derivatives
GB0315870A GB2392910A (en) 2002-09-10 2003-07-07 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors

Publications (1)

Publication Number Publication Date
MA27431A1 true MA27431A1 (fr) 2005-07-01

Family

ID=31998571

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28139A MA27431A1 (fr) 2002-09-10 2005-03-10 Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques

Country Status (14)

Country Link
US (1) US7687510B2 (fr)
EP (1) EP1546113B1 (fr)
KR (1) KR20050042190A (fr)
AU (1) AU2003282006C1 (fr)
BR (1) BR0314186A (fr)
CA (1) CA2498051C (fr)
HR (1) HRP20050318A2 (fr)
MA (1) MA27431A1 (fr)
MX (1) MXPA05002644A (fr)
NO (1) NO20051726L (fr)
NZ (1) NZ538670A (fr)
PL (1) PL375647A1 (fr)
UY (1) UY27965A1 (fr)
WO (1) WO2004024700A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539710B1 (fr) * 2002-09-10 2010-10-27 Bayer Schering Pharma Aktiengesellschaft Derives heterocycliques
JP3981133B2 (ja) 2002-09-26 2007-09-26 ロレアル ブロックポリマーおよび皮膜形成剤を含む組成物
US8097629B2 (en) * 2004-02-19 2012-01-17 Bayer Pharma Aktiengesellschaft Dihydropyridinone derivatives
WO2005082863A2 (fr) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Derives heterocycliques
JP4825194B2 (ja) * 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
CA2590851A1 (fr) * 2004-12-16 2006-06-22 Bayer Healthcare Ag Structure cristalline d'enzyme et utilisations associees
GB0502258D0 (en) * 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0512940D0 (en) * 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (fr) 2005-08-08 2008-05-28 Argenta Discovery Limited Dérivés bicyclo[2.2.]hept-7-ylamine et leurs utilisations
WO2009013444A1 (fr) * 2007-07-25 2009-01-29 Argenta Discovery Limited Tétrahydropyrrolopyrimidinediones et leur utilisation comme inhibiteurs de l'élastase des neutrophiles humains
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
AU2007246889B2 (en) 2006-05-04 2011-03-10 Chiesi Farmaceutici S.P.A. Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
DE102006031314A1 (de) * 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
WO2009060158A1 (fr) * 2007-11-07 2009-05-14 Argenta Discovery Limited Dérivés de 4-(4-cyanophényl)-1-(3-trifluorométhylphényl)-3,4,6,7-tétrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-dione et leur utilisation en tant qu'inhibiteurs de l'élastase des neutrophiles humains
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
BRPI0821027B8 (pt) * 2007-12-20 2021-05-25 Bayer Ip Gmbh 4-(4-ciano-2-tioaril)di-hidropirimidinonas para tratamento e/ou prevenção de lesões do pulmão e do sistema cardiovascular, seu processo de preparação e seu uso, e medicamento
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008052013A1 (de) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
CA2727199C (fr) * 2008-06-09 2016-11-22 Bayer Schering Pharma Aktiengesellschaft Derives condenses de la 4-(indazolyl)-1,4-dihydropyridine et leurs procedes d'utilisation
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
DE102009016553A1 (de) * 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
JP2013177318A (ja) * 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd ジヒドロピリミジノン誘導体およびその医薬用途
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN106661008A (zh) 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016146607A1 (fr) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Procédé de production de (4s)-4-[4-cyano-2-(méthylsulfonyl)phényl]-3,6-diméthyl-2-oxo-1-[3-(trifluorométhyl)phényl]-1,2,3,4-tétrahydro pyrimidine-5-carbonitrile
US9856232B1 (en) 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives
US10111873B1 (en) 2018-01-17 2018-10-30 King Saud University Dihydropyrimidinone derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216272D0 (en) 1991-08-15 1992-09-09 Ici Plc Substituted heterocycles
GB9214053D0 (en) * 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
EP1248624A4 (fr) * 1999-11-23 2003-01-22 Smithkline Beecham Corp 3,4-dihydro-(1h)-quinazolein-2-ones et leur utilisation en tant qu'inhibiteurs de la kinase csbp/p38

Also Published As

Publication number Publication date
AU2003282006C1 (en) 2009-11-26
CA2498051A1 (fr) 2004-03-25
NZ538670A (en) 2007-01-26
MXPA05002644A (es) 2005-09-20
US20060160801A1 (en) 2006-07-20
PL375647A1 (en) 2005-12-12
BR0314186A (pt) 2005-08-09
UY27965A1 (es) 2004-04-30
US7687510B2 (en) 2010-03-30
CA2498051C (fr) 2012-05-15
KR20050042190A (ko) 2005-05-04
EP1546113B1 (fr) 2013-05-01
AU2003282006B2 (en) 2009-06-04
NO20051726L (no) 2005-04-07
WO2004024700A1 (fr) 2004-03-25
EP1546113A1 (fr) 2005-06-29
HRP20050318A2 (en) 2006-07-31
AU2003282006A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
MA27431A1 (fr) Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques
ATE516285T1 (de) Dihydropyridinonderivate
WO2005082863A3 (fr) Derives heterocycliques
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
DE69324151D1 (de) Inhibitoren des arginin-ketoamid-enzyms
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
BR0009167A (pt) Inibidores de enzima impdh
MA27316A1 (fr) Derives d'indoline-phenylsulfonamide
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20075134L (no) Bestemte substituerte amider, fremgangsmate for femstilling derav og anvendelse derav
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
ECSP055669A (es) Derivados de pirimidinona como agentes terapéuticos contra procesos de remodelación, isquemicos e inflamatorios agudos y cronicos
ATE318601T1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
BRPI0410466A (pt) derivados de indol como inibidores de fator xa
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
ECSP055844A (es) Nuevos compuestos triciclicos